Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O14640

UPID:
DVL1_HUMAN

ALTERNATIVE NAMES:
DSH homolog 1

ALTERNATIVE UPACC:
O14640; Q5TA33; Q5TA35

BACKGROUND:
The protein Segment polarity protein dishevelled homolog DVL-1, alternatively named DSH homolog 1, is integral to the Wnt signaling pathway, impacting both canonical and non-canonical signaling routes. It is crucial for the activation of LEF1 in response to WNT1 and WNT3A and is involved in the formation of the neuromuscular junction through a complex with DVL1 and PAK1.

THERAPEUTIC SIGNIFICANCE:
Given its role in the pathogenesis of Robinow syndrome, autosomal dominant 2, DVL-1 presents a promising target for therapeutic intervention. This condition, marked by unique facial features, limb abnormalities, and renal issues, could benefit from advances in understanding DVL-1's function.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.